MedPacto "US Investor Licenses Liver Disease Treatment Technology to French Pharmaceutical Company"

MedPacto announced on the 31st that its U.S. subsidiary, Celloram, has signed a licensing agreement with the French pharmaceutical company Genfit for the inflammasome inhibitor 'CLM-022.'

Under this agreement, Celloram will transfer the global rights to develop CLM-022 as a treatment for liver diseases to Genfit. The contract is valued at a total of 160 million euros (approximately 225 billion KRW), including milestones. Specific details will remain confidential as agreed by both parties.

The inflammasome inhibitor CLM-022 suppresses the activation of the NLRP3 inflammasome, which influences the onset of various human diseases such as autoinflammatory disorders, metabolic syndrome, and neurodegeneration, thereby exerting strong anti-inflammatory and antioxidant effects to inhibit inflammatory diseases.

Inflammasome inhibitors are currently a focus area in the global pharmaceutical and biotech market, with many global pharmaceutical companies researching inflammasome inhibitors for various indications.

Genfit is a global pharmaceutical company developing treatments for liver diseases such as acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA). Genfit has shown interest in inflammasome inhibitors to expand its liver disease treatment pipeline. By licensing Celloram's CLM-022, Genfit has secured a new pipeline for liver disease treatment development.

Celloram also confirmed the potential of CLM-022 through this agreement and plans to continue research on various indications beyond liver diseases in the future.

Tej Pareek, CEO of Celloram, stated, “Genfit highly evaluated the potential of our inflammasome inhibitor ‘CLM-022’ as a treatment for liver diseases, which led to the successful conclusion of this agreement,” adding, “Celloram will continue the development of CLM-022 not only for liver diseases but also for other indications.”

Meanwhile, Celloram, located in Cleveland, Ohio, USA, is a biotech company with strengths in immunology and inflammation, focusing on autoimmune diseases, cancer vaccines, and inflammatory diseases. It was co-founded by Kim Sung-jin, CEO of MedPacto, and John Letterio, Director of the Pediatric Oncology Center at Cleveland Medical Center. Dr. John Letterio is a world-renowned expert in immunology and inflammation and contributed to MedPacto’s early research.

This content was produced with the assistance of AI translation services.